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Aims: May Measurement Month is a global screening campaign to raise awareness
regarding elevated blood pressure (BP). With the growing burden of hypertension, it
is imperative to regularly assess the disease’s prevalence, risk factors, and aware-
ness levels in a country. The current prevalence of hypertension in India as per the
National Family Health Survey Data stands at 25.3%. May Measurement Month
mobilizes healthcare professionals and sensitizes them to regularly measure BP, and
impart lifestyle modification advice to the community. It also complements the
deficiency in screening programmes at a national and international level.
Methods and results: May Measurement Month was carried out in May 2019 as an
opportunistic screening campaign for adults (18 years). It was carried out by over
5000 trained volunteers across approximately 1000 screening sites (hospitals,
public places, pharmacies, villages, and malls) in India. A total of 362 708 (57%
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males and 42.7% females) people were screened, among whom 68.1% had never
measured their BP, and 29.4% (n¼ 106 522) were found to have hypertension. Of
these, only 42.0% were on antihypertensive medication and 23.3% had controlled
hypertension.
Conclusion: Almost a third of the screened population had hypertension, and less
than half of those with hypertension were aware of it or on treatment for it.
Among those on antihypertensive drugs, BP was controlled in only half of them.
These results support the need for greater impetus on BP screening initiatives to
detect hypertension early in the community and prevent complications due to
uncontrolled BP.
Introduction
The last few decades have seen an increase in the preva-
lence of hypertension in India.2 Hypertension, often re-
ferred to as the ‘silent killer’, is known to cause various
complications such as stroke, retinopathy, ischaemic heart
disease, aneurysms, and renal disease. A staggering 57.0%
of stroke and 24.0% of coronary artery related deaths have
been attributed to hypertension.1 Over the past five deca-
des, researchers have established hypertension as a consis-
tent and resilient risk factor that doubles the mortality and
mortality burden with an increase of systolic blood pres-
sure (BP) level of 20 mmHg.3 Nearly, 10.8% of all deaths in
India and 28.0% of mortality due to cardiovascular diseases
are attributed to hypertension.4
The May Measurement Month (MMM) initiative, concep-
tualized by the International Society of Hypertension, is a
stride in the right direction towards improving awareness
regarding this silent killer. India has been an active partici-
pant in this campaign since 2017. In 2017, 31.8% of the to-
tal participants (240 376) were found to be hypertensive
based on all three BP readings, whereas 14.0% (n¼ 122
685) were on antihypertensive treatment. This campaign
in 2018 saw a similar prevalence of hypertension at 32.3%
(n¼ 345 234).5
Awareness regarding hypertension, its prevention, and
control is low in the community leading to poorly managed
BP levels.6,8 Identifying hypertension in the community,
sensitizing the population towards the regular measure-
ment of BP, and improvingmedication compliance is crucial
for managing and controlling hypertension.
Methods
Multiple study coordinators led the MMM campaign in India
and were responsible for training the volunteers in BP mea-
surement techniques and disseminating lifestyle guidance.
May Measurement Month 2019 India was conducted in over
1000 sites with more than 5000 volunteers [doctors, nurses,
dieticians, allied health care professionals, Anganwadi
workers (ANM), pharmacists, doctors in training, and stu-
dents]. The ethical clearances were taken at the local
screening sites by the respective site coordinators and in-
formed consent was taken from each respondent. The MMM
campaign involved a volunteer drive by various national
organizations and associations (Public Health Foundation of
India, Indian Society of Hypertension, Indian Association for
Parenteral and Enteral Nutrition, and Rural Health Progress
Trust), social media campaigns, and educational institutes.
The screening was conducted in public places such as malls,
metro stations, villages, offices, housing complexes, reli-
gious homes (temples, churches, etc.), pharmacies, clinics,
and hospitals, using amercury sphygmomanometer or a digi-
tal BP machine. The site coordinators obtained ethical
clearance for the screening sites. The screening for BP con-
tinued through May (1st May to 31st May 2019) and was ex-
tended to 31st July 2019. Data were collected on Microsoft
Excel sheets and an app developed by ISH. The MMM project
team at ISH collated, cleaned, and analysed the data.
Blood pressure was recorded three times in the seated po-
sition by the volunteers, while height and weight were ei-
ther self-reported or measured at the screening site.
Multiple imputations were used to calculate the mean of
second and third readings where the measurements were
missing, based on the global data.6 Hypertension was de-
fined as a systolic BP  140mmHg or a diastolic BP 
90mmHg or on hypertension treatment.5 May Measurement
Month 2019 captured data that were not collected in previ-
ous years, including number of antihypertensive drug classes
being consumed, location of screening site, use of aspirin or
statin, and if the participants were fasting.
Results
Of the total 362 708 participants screened, 92.5% were of
South Asian ethnicity. The population had a mean age of
43.4 (SD: 616.0) years, 57.0% were males, and 2.6% of
women were pregnant at the time of screening. The BP
screenings took place mostly in public areas (47.6%) and
hospitals or clinics. Over two-thirds of the participants
(247 057 (68.1%) had their BP measured for the first time
ever. About one-tenth of the participants (11.3%) were pre-
viously diagnosed with diabetes, 6.0% had a history of myo-
cardial infarction and 5.1% of stroke. Aspirin and statin
consumption was reported in 5.9% and 7.2% of participants,
respectively. A large majority of the participants did not
report consuming alcohol (91.4%) or smoking (81.1%), and
6.6% of them were fasting. The mean body mass index of
participants was 24.5 (SD:6 4.9) kg/m2.
After imputation, 29.4% (106 522) of respondents were
hypertensive; of these, 46 646 (43.8%) were aware of being
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hypertensive, and 44 710 (42.0%) were on antihypertensive
treatment. A total of 24 795 hypertensive patients (23.3%)
of all hypertensive participants had controlled BP (systolic
BP <140mmHg and diastolic BP <90mmHg), while BP was
uncontrolled in 19 915 (44.5%) of those on BP-lowering
medications (n¼ 44 710).
For respondents with three BP readings (n¼ 295 517),
the mean of second and third readings (126.0/79.1mmHg)
was similar to the mean of all three measurements (126.6/
79.4mmHg). The age and sex standardized mean BP for
those on antihypertensive medication was 135.5/82.5mmHg
and 123.9/78.1mmHg in those not on treatment. Excluding
those on treatment, systolic BP was seen rising with age in
women while in men it peaked around 65years of age, fol-
lowed by a small decline. The diastolic BP showed lesser vari-
ability but similar trends as systolic BP. Linear regression
models adjusted for age, sex and, use of antihypertensive
drugs showed that the mean BP was significantly higher in
known cases of diabetes and hypertension, and people on
BP-lowering medications (adjusted for age and sex alone),
while it was lower for those with previous myocardial infarc-
tion and stroke. Compared to readings taken in a hospital or
clinic, linear regressionmodels for the difference inmean BP
at each screening site type showed significantly lower sys-
tolic and diastolic BP levels when taken in indoor public
spaces, but systolic BPreadings were higher in outdoor public
spaces, in workplaces and pharmacies. There is a significant
increase in both systolic BP and diastolic BP in those drinking
alcohol one or more times per week compared to never
drinking (Figure 1).
Discussion
With a third of the screened population (n¼ 362 708)
being hypertensive and less than half of them aware of
being hypertensive, MMM has proven to be an important
initiative towards the detection of raised BP. The
proportion of hypertension in MMM19 (29.4%) has not
been much different than what was reported in MMM17
(31.2%) and MMM18 (32.3%), as well as the global MMM
20173 and 20184 data (34.9% and 33.4%, respectively).
Of the 42% of participants that were on BP-lowering
drugs, 45% had uncontrolled BP, which is higher than the
40.1% seen globally.7 These results point to the need for
enhanced BP awareness efforts, establishing standardized
BP management strategies, and addressing the burden of
risk factors of hypertension, including obesity, alcohol in-
take, and medication compliance.
May Measurement Month limitations include assessment
of BP in a single instance, thus increasing the chances of in-
accurate diagnosis. May Measurement Month in India was
an opportunistic screening; therefore, the sampling was
not random and not representative of India’s population.
Moreover, the efficacy of lifestyle advice given to the par-
ticipants could not be evaluated in this study.
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Figure 1 Difference in mean blood pressure in those with each risk factor compared to those without from linear regression models adjusted for age,
sex and, antihypertensive medication (pregnancy adjusted for age and antihypertensive medication alone).
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